CN109563135B - α(V)β(6)整合素结合肽及其使用方法 - Google Patents

α(V)β(6)整合素结合肽及其使用方法 Download PDF

Info

Publication number
CN109563135B
CN109563135B CN201780049057.2A CN201780049057A CN109563135B CN 109563135 B CN109563135 B CN 109563135B CN 201780049057 A CN201780049057 A CN 201780049057A CN 109563135 B CN109563135 B CN 109563135B
Authority
CN
China
Prior art keywords
conjugate
peptide
integrin
alpha
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780049057.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563135A (zh
Inventor
曾昭莹
朱莉·L·苏特克利夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN109563135A publication Critical patent/CN109563135A/zh
Application granted granted Critical
Publication of CN109563135B publication Critical patent/CN109563135B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780049057.2A 2016-06-13 2017-06-13 α(V)β(6)整合素结合肽及其使用方法 Active CN109563135B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349615P 2016-06-13 2016-06-13
US62/349,615 2016-06-13
PCT/US2017/037303 WO2017218569A2 (en) 2016-06-13 2017-06-13 Alpha(v)beta(6) integrin-binding peptides and methods of use thereof

Publications (2)

Publication Number Publication Date
CN109563135A CN109563135A (zh) 2019-04-02
CN109563135B true CN109563135B (zh) 2024-01-23

Family

ID=60664208

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780049057.2A Active CN109563135B (zh) 2016-06-13 2017-06-13 α(V)β(6)整合素结合肽及其使用方法

Country Status (7)

Country Link
US (2) US11185601B2 (enExample)
EP (1) EP3468984A4 (enExample)
JP (1) JP7081832B2 (enExample)
CN (1) CN109563135B (enExample)
AU (1) AU2017283537B2 (enExample)
CA (1) CA3027364A1 (enExample)
WO (1) WO2017218569A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015160770A1 (en) * 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
WO2017218569A2 (en) 2016-06-13 2017-12-21 The Regents Of The University Of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
WO2020051549A1 (en) 2018-09-07 2020-03-12 The Regents Of The University Of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
AU2021210878A1 (en) * 2020-01-21 2022-09-15 Quantum-Si Incorporated Compounds and methods for selective C-terminal labeling
IL296081A (en) * 2020-03-12 2022-11-01 Univ Muenchen Tech Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo
MX2023006483A (es) * 2020-12-04 2023-07-20 Univ California Terapia radionuclidica de receptores peptidicos.
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer
WO2024263637A1 (en) 2023-06-20 2024-12-26 The Regents Of The University Of California Combination therapy with peptide receptor radionuclide and dna repair inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939384A (zh) * 2007-07-31 2011-01-05 通用电气健康护理有限公司 肽显像剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429133A (en) * 1992-12-18 1995-07-04 Neoprobe Corporation Radiation responsive laparoscopic instrument
DE10154180A1 (de) * 2001-11-05 2003-05-15 Basf Ag gene die für genetische Stabilitäts-, genexpressions-und Faltungsproteine codieren
DE602004023534D1 (de) 2003-11-18 2009-11-19 Mitsubishi Gas Chemical Co Verfahren zur herstellung von optisch aktivem 2-alkylcystein, derivate davon und herstellungsverfahren
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
WO2015160770A1 (en) * 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
WO2017218569A2 (en) 2016-06-13 2017-12-21 The Regents Of The University Of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939384A (zh) * 2007-07-31 2011-01-05 通用电气健康护理有限公司 肽显像剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PREDICTED: uncharacterized protein LOC107006195 [Solanum pennellii]，NCBI Reference Sequence: XP_015060296.1;NONE;《GenBank Database》;20151223;ORIGIN部分 *

Also Published As

Publication number Publication date
EP3468984A4 (en) 2020-03-11
US20190328910A1 (en) 2019-10-31
AU2017283537B2 (en) 2021-11-11
CN109563135A (zh) 2019-04-02
US12023391B2 (en) 2024-07-02
EP3468984A2 (en) 2019-04-17
AU2017283537A1 (en) 2019-01-03
JP2019524871A (ja) 2019-09-05
JP7081832B2 (ja) 2022-06-07
WO2017218569A2 (en) 2017-12-21
US20220047730A1 (en) 2022-02-17
WO2017218569A3 (en) 2018-02-01
US11185601B2 (en) 2021-11-30
CA3027364A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
CN109563135B (zh) α(V)β(6)整合素结合肽及其使用方法
US11485758B2 (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
US9073974B2 (en) RGD-containing cyclic peptides
US11591369B2 (en) Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
US20060019900A1 (en) Alpha-4 beta-1 integrin ligands for imaging and therapy
ES2840323T3 (es) Variantes de péptidos dirigidos a tumores
WO2020072491A1 (en) Brevican-binding peptides for brain tumor imaging
HK1234666B (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
HK1234666A1 (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant